What are the limitations of the cll ipi score?

While the cll ipi score is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the cll ipi score to ensure safe bedside use and optimal diagnostic accuracy.

How does the cll ipi score compare to other Hematology scores?

The cll ipi score is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the cll ipi score free to use?

Yes. OpiCalc provides the cll ipi score completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

935 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

CLL-IPI

CLL-IPI: Validated prognostic index for treatment-naive CLL. Integrates genetic, biochemical, and clinical markers to predict 5-year survival.

CLL-IPI Total Score

0

Risk Category

Low

93.2% 5-year Survival

Active surveillance ('Watch and Wait') is typically appropriate unless symptomatic.

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostication in patients with Chronic Lymphocytic Leukemia (CLL).

To guide the decision of "watch and wait" vs. active therapy.

Identifying high-risk patients who may benefit from novel agents (BTKi, BCL2i) early in the disease course.

Patient Population

Validated in large international cohorts of treatment-naive CLL patients. Applicable at the time of diagnosis or prior to first-line therapy.

When Not to Rely on This Score Alone

Relapsed/Refractory CLL — the score was primarily derived for treatment-naive patients.

To decide on treatment initiation — the decision to treat should be based on iwcll 2018 criteria (e.g., marrow failure, bulky nodes, symptoms) regardless of IPI score.

Small Lymphocytic Lymphoma (SLL) — while similar, the score was specifically validated for CLL.

Section 2

Formula & Logic

Scoring Variables

Variable	Criteria	Weight
TP53 Status	Del(17p) and/or TP53 mutation	4
IGHV Status	Unmutated (≥ 98% identity)	2
β2-Microglobulin	> 3.5 mg/L	2
Clinical Stage	Rai I-IV or Binet B-C	1
Age	> 65 years	1

Risk Groups

Score	Risk Group	5-year OS	Management Strategy
0 - 1	Low	93.2%	Watch and wait
2 - 3	Intermediate	79.3%	Watch and wait unless symptomatic
4 - 6	High	63.3%	Consider treatment if symptomatic
7 - 10	Very High	23.3%	Novel agents or clinical trial

Section 3

Pearls/Pitfalls

Modern Era Applicability

The CLL-IPI was developed in the chemo-immunotherapy (CIT) era. While it remains a powerful prognostic tool, its ability to predict survival in the era of continuous BTK inhibitors (ibrutinib, acalabrutinib) and venetoclax is still evolving, though it remains highly discriminative for time-to-first-treatment.

The TP53/IGHV Multiplier

The heavy weighting of TP53 (4 points) and IGHV unmutated status (2 points) reflects the biological dominance of these factors over clinical stage in predicting CLL behavior.

Section 4

Evidence Appraisal

Derivation Study

An international prognostic index that predicts survival in patients with chronic lymphocytic leukaemia (CLL-IPI): an analysis of individual patient data.

International CLL-IPI working group. • Lancet Oncology. 2016;17(6):779-790. n=3472 across 8 multicentre trials.

View Source

Section 5

Literature

Development

Developed by an international consortium of CLL study groups (German, French, British, Mayo Clinic, etc.) to unify various disparate prognostic systems into a single validated index.

Last Comprehensive Review: 2026

Related Hematology Tools

Sokal/EUTOS/ELTS Comparison

IPSID / Lugano Classification

Deauville Score Interpreter

Have feedback about this calculator?Let us know.